Literature DB >> 9756789

In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.

A Gikas1, I Spyridaki, A Psaroulaki, D Kofterithis, Y Tselentis.   

Abstract

The antibiotic susceptibilities of eight Greek isolates of Coxiella burnetii to trovafloxacin were determined by the shell vial assay. MICs of trovafloxacin and ofloxacin ranged from 1 to 2 microg/ml, those of pefloxacin ranged from 1 to 4 microg/ml, those of ciprofloxacin ranged from 4 to 8 microg/ml, those of doxycycline ranged from 1 to 2 microg/ml, and those of clarithromycin ranged from 2 to 4 microg/ml. Trovafloxacin exhibited no activity against C. burnetii at 4 microg/ml.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756789      PMCID: PMC105931     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm.

Authors:  M Maurin; A M Benoliel; P Bongrand; D Raoult
Journal:  J Infect Dis       Date:  1992-11       Impact factor: 5.226

2.  Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.

Authors:  D Raoult; H Torres; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 3.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

Review 4.  Q fever.

Authors:  D Raoult; T Marrie
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

Review 5.  Treatment of Q fever.

Authors:  D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

6.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  Susceptibility of Rickettsia conorii, R. rickettsii, and Coxiella burnetii to PD 127,391, PD 131,628, pefloxacin, ofloxacin, and ciprofloxacin.

Authors:  N Jabarit-Aldighieri; H Torres; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 8.  Antibiotic treatment of rickettsiosis, recent advances and current concepts.

Authors:  D Raoult
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

9.  In vitro activities of ceftriaxone and fusidic acid against 13 isolates of Coxiella burnetii, determined using the shell vial assay.

Authors:  H Torres; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Q fever in the Greek Island of Crete: epidemiologic, clinical, and therapeutic data from 98 cases.

Authors:  Y Tselentis; A Gikas; D Kofteridis; E Kyriakakis; N Lydataki; D Bouros; N Tsaparas
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

View more
  15 in total

1.  Use of macrolides for Q fever.

Authors:  Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  Diagnosis of quinolone-resistant Coxiella burnetii strains by PCR-RFLP.

Authors:  I Spyridaki; A Psaroulaki; A Aransay; E Scoulica; Y Tselentis
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 3.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 4.  Antimicrobial therapies for Q fever.

Authors:  Gilbert J Kersh
Journal:  Expert Rev Anti Infect Ther       Date:  2013-09-27       Impact factor: 5.091

5.  Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii.

Authors:  J M Rolain; M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.

Authors:  Jean-Marc Rolain; Areen Boulos; Marie-Noëlle Mallet; Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; E Scoulica; A Psaroulaki; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Evaluation of Coxiella burnetii antibiotic susceptibilities by real-time PCR assay.

Authors:  Robert E Brennan; James E Samuel
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.

Authors:  I H Norville; G J Hatch; K R Bewley; D J Atkinson; K A Hamblin; J D Blanchard; S J Armstrong; J K Pitman; E Rayner; G Hall; J Vipond; T P Atkins
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

10.  Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.

Authors:  Ioanna Spyridaki; Anna Psaroulaki; Iosif Vranakis; Yannis Tselentis; Achilleas Gikas
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.